|Epigenomics AG -- USA Stock|| |
USD 5.34 0.18 3.49%
Mr. Gregory Hamilton is Chief Executive Officer of Epigenomics AG since July 1, 2016. He has over 20 years of management experience in molecular diagnostics, manufacturing and professional service industries. Prior to joining Epigenomics, Mr. Hamilton was Chief Executive Officer Director of AltheaDx Inc., Chief Operating Officer and Chief Financial Officer of Enigma Diagnostics Inc., Vice President of Operations and Finance at Third Wave Technologies Inc. and Vice President of Operations at Hologic Inc. He was responsible for multiple FDAcleared products including a Human Papilloma Virus High Risk Screening assay and the first ever cleared HPV genotyping assay
Age: 46 CEO Since 2016 MBA
49 30 243 450 http://www.epigenomics.com
Hamilton received his MBA from the University of Chicago and his BS in Finance from Purdue University.
The company has return on total asset (ROA)
of (44.29) %
which means that it has lost $44.29 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (122.69) %
meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 607.04 K in total debt with debt to equity ratio (D/E) of 5.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Epigenomics AG has Current Ratio of 1.92 which is within standard range for the sector.
Epigenomics AG, a molecular diagnostics company, focuses on developing and commercializing in vitro diagnostic tests for the screening, early detection, and diagnosis of cancer in Germany and internationally. Epigenomics AG (EPGNF) is traded on OTC Market in USA. It is located in Berlin, and employs 43 people.